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Abstract 
Disease progression and drug response may vary significantly from patient to patient. Fortunately, the rapid develop-
ment of high-throughput ‘omics’ technologies has allowed for the identification of potential biomarkers that may aid 
in the understanding of the heterogeneities in disease development and treatment outcomes. However, mechanistic 
gaps remain when the genome or the proteome are investigated independently in response to drug treatment. In 
this article, we discuss the current status of pharmacogenomics in precision medicine and highlight the needs for 
concordant analysis at the proteome and metabolome levels via the more recently-evolved fields of pharmacopro-
teomics, toxicoproteomics, and pharmacometabolomics. Integrated ‘omics’ investigations will be critical in piecing 
together targetable mechanisms of action for both drug development and monitoring of therapy in order to fully 
apply precision medicine to the clinic.
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Background
Too many patients suffer from diseases with no known 
cure or effective treatment. Therapeutic modalities may 
be efficacious in some individuals or be associated with 
treatment failure and toxicities in others. It is well known 
that heterogeneities of disease presentation, genetics, 
and environment all contribute to the variability in drug 
response. With the vast improvements in technologies such 
as genome sequencing, big-data analysis, and electronic 
health records, healthcare is being revolutionized from 
a “one-size-fits-all” approach to a focus on the individual 
patient. In his 2015 State of the Union address, U.S. Presi-
dent Obama announced the Precision Medicine Initiative. 
The goal of the precision medicine approach is to integrate 
genetic and environmental information to have the ability 
to classify subpopulations of patients based on their suscep-
tibility to particular diseases and/or their responses to par-
ticular treatments. In this manner, diagnostic testing can be 
used to optimize therapies for an individual. In support of 
this initiative, Congress recently approved the largest fund-
ing increase for biomedical research in 12  years, giving 
the NIH a $2 billion increase that contained $200 million 
for the Precision Medicine Initiative in 2016 [1]. A main 
mission of the initiative will be the assembly of a national 
research participant cohort of over 1  million Americans 
[2]. Data collected from the cohort will ideally allow for the 
identification of pharmacogenomic drug-gene relationships 
as well as the discovery of new biomarkers and therapeutic 
targets. This initiative comes at a time when technological 
advances have shifted biomedical studies from single genes, 
proteins, and metabolites to all-encompassing genomes, 
proteomes, and metabolomes. This review will highlight 
how recent progressions in both genomics and proteomics 
have contributed to and will continue to be simultaneously 
necessary for the administration of therapeutic regimens 
with the highest probability of success.
Pharmacogenomics
With advances in sequencing technology and follow-ups 
to the Human Genome Project, such as the International 
HapMap Project and the 1000 Genomes Project, much of 
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the focus for precision medicine thus far has been in the 
field of genomics. While a patient’s response to a drug is 
affected by many factors, such as drug dose, adherence 
and compliance to a dosing regimen, and drug–drug 
interactions, genetic variation in genes encoding for drug-
metabolizing enzymes and transporter proteins also plays 
a significant role. Such genetic variation may drastically 
impact drug pharmacokinetics through modulation of 
drug absorption, distribution, metabolism, or elimination. 
With standard doses of implicated drugs, individuals with 
this type of genetic variation may experience adverse drug 
reactions due to drug concentrations that may either be 
toxic or non-efficacious. For example, single nucleotide 
polymorphisms (SNPs), particularly within genes encod-
ing for the cytochrome P450 family of enzymes, have 
been widely implicated in aberrant drug metabolism [3].
Pharmacogenomics approaches and applications
Genetic mutations influencing drug metabolism may be 
explored in a targeted single-gene manner (pharmacoge-
netics) or in a more global, whole-genome manner (phar-
macogenomics) [4]. Single gene-drug responses, also 
known as candidate-gene studies, were traditionally the 
focus of investigations and have resulted in most of the 
well-established pharmacogenetic markers to date. How-
ever, improvements in broad-range sequencing technolo-
gies, including the completion of the Human Genome 
Project, have allowed for the increasing application of 
pharmacogenomic, genome-wide association studies. 
Such approaches allow largely unbiased investigation 
into genes or genetic pathways that may be involved in 
drug response. In vivo human experiments are ideal for 
these studies when they can be performed safely. Typi-
cally, patient samples are grouped by phenotype, such 
as patients who experienced efficacious drug effects 
versus no effect, or patients who experienced particular 
adverse reactions or toxic effects from standard doses. 
DNA is analyzed by broad, high-throughput sequencing 
approaches such as SNP microarrays, digital PCR, and 
next-generation sequencing. Data quality checks are crit-
ical to determine SNPs that were successfully genotyped, 
and appropriate allele frequency models are used to cal-
culate accurate odds ratios and pinpoint candidate SNPs 
[5]. Animal studies and in vitro cell line approaches are 
practical alternatives for pharmacogenomic studies when 
drug toxicity is of concern [6, 7]. In particular, lympho-
blastoid cell lines transformed with the human Epstein–
Barr virus, resulting in immortalized B lymphocytes, 
have shown tremendous utility as a model to assess ger-
mline genetic contribution to both positive and adverse 
drug responses [8]. The NCI-60 cancer cell panel is also 
widely used to investigate the effect of somatic mutations 
on drug response [9].
A hallmark genome-wide drug response study in 
human patients was reported in 2008 by the Study of 
the Effectiveness of Additional Reductions in Choles-
terol and Homocysteine (SEARCH) Collaborative Group, 
which sought to determine reasons for rare cases of sta-
tin-induced myopathy and rhabdomyolysis [10]. Assess-
ment of over 300,000 SNP locations by bead array in 
patients taking equivalent doses of simvastatin revealed 
a strong correlation of myopathy (defined as elevated 
serum creatine kinase levels) with a particular SNP on 
the SLCO1B1 gene, which encodes a protein involved 
in the hepatic uptake of various drugs. The finding led 
the group to further sequencing of other regions on 
SLCO1B1 and resulted in the identification of several 
other common variants of the gene that were strongly 
associated with statin-induced myopathy. A recent pilot 
study showed that patients who received SLCO1B1 
genetically-guided statin therapy management were 
more likely to comply with dosing regimens and lower 
their LDL-cholesterol [11].
Genome-wide pharmacogenomic studies have more 
recently been applied in a wide variety of clinical appli-
cations, including investigations into drug concentra-
tions and related effects of additional cholesterol- and 
lipid-lowering molecules [12–14], anti-depressants [15, 
16], and cancer treatments [17, 18]. While most tradi-
tional cancer genomics initiatives focused on identify-
ing the somatic mutations that drive tumor progression, 
it is now also recognized that germline variation among 
patients may significantly impact their response to cancer 
treatments. Initially, candidate-gene studies established 
associations such as CYP2D6 polymorphisms and poor 
outcomes of breast cancer after tamoxifen treatment 
[19], or toxicity-inducing UGT1A1 polymorphisms with 
irinotecan treatment of colon cancer [20]. Both of these 
pharmacogenetic associations have since been used to 
guide dosages of these drugs in a clinical setting [21, 22] 
and are included in expert consensus guidelines offered 
by the Clinical Pharmacogenetics Implementation Con-
sortium (CPIC) [23]. Currently, there are increasing 
genome-wide association studies which serve to discover 
novel genetic biomarkers associated with variant can-
cer drug efficacy or toxicity in a broad, high-throughput 
manner. An unprecedented genome-wide study into the 
genetic association of variable outcomes of 5-fluoroura-
cil and oxaliplatin (FOLFOX) treatments for colorec-
tal cancer patients used SNP array technology to reveal 
seven SNPs significantly correlated with gastrointesti-
nal, hematological, and neurological adverse drug reac-
tions [24]. Recently, a similarly-designed study found two 
SNPs associated with myelosuppression in non-small 
cell lung cancer patients receiving platinum-based thera-
pies [25]. Such associations would likely have never been 
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discovered without the use of unbiased genome-wide 
approaches. However, functional studies are needed to 
further understand the pathways and mechanisms asso-
ciated with these genetic aberrations in order to consider 
them for clinical use.
Future directions for pharmacogenomics
Future directions for pharmacogenomics studies will likely 
involve incorporation of epigenetic factors such as DNA 
methylation and histone modification into assessment 
of drug response. Epigenetics may explain heterogenei-
ties in phenotype when genotype is identical. Epigenetic 
modifications have largely been implicated in cancer, 
among other diseases, and represent an important class of 
drug targets [26, 27]. Indeed, DNA methylation has been 
shown to play a significant role in regulating the expres-
sion of members of the cytochrome P450 superfamily 
of enzymes, which is responsible for the metabolism of 
over 75 percent of commonly-prescribed pharmaceuti-
cals [28–30]. While significant evidence exists in the lit-
erature for the epigenetic regulation of genes involved in 
the absorption, distribution, metabolism, and excretion 
(ADME) of drugs [31], the clinical relevance of this reg-
ulation remains to be seen. Combined broad-screening 
genomic and epigenetic studies are emerging [32] and 
will be critical to directly link genotypes with phenotypes. 
Additionally, increased accessibility to next generation 
sequencing will allow for the identification and analysis 
of novel, unique variants that may be missed by the SNP 
array-based methods [33]. In 2012, Price et al. described 
the first use of whole exome sequencing to identify novel, 
non-CYP2C19 genetic variants correlated to aberrant 
platelet responsiveness to clopidogrel [34]. More recently, 
whole exome sequencing also led to genetic determinants 
in exceptional responders to targeted anticancer therapy 
of pazopanib and everolimus in advanced solid tumors 
[35]. Indeed, as sequencing costs continue to decrease, 
pharmacogenetic testing in the clinic may shift from 
targeted assays for specific drugs to pre-emptive, broad-
scale testing models using interpretive guides from such 
resources as CPIC [23, 36].
Pharmacoproteomics
While the aforementioned genomic studies have pro-
vided an abundance of advancing information and clini-
cal utility, it is at the protein level that cellular processes 
are functionally regulated. Expression levels of genes and 
their transcripts do not necessarily correlate with cor-
responding protein abundance [37]. While there are an 
estimated 19,000 protein-coding genes in the human 
genome [38], it is likely that the number of proteins is 
near or into the millions, taking into consideration the 
vast opportunities for posttranslational modification that 
exponentially increase the diversity of the human pro-
teome. Additionally, while DNA sequencing approaches 
provide static snapshots of cellular processes, the more 
dynamic nature of proteins makes them ideal for study-
ing kinetic responses to drug treatments. Thus, it would 
be beneficial for wide-scale genomic studies to be paired 
with analysis of the proteome. Indeed, a major limita-
tion of the aforementioned genome-wide associated 
pharmacogenomics studies is the lack of understanding 
of the true biological mechanisms and complete cellular 
pathways underlying the identified genetic associations. 
Precision medicine should therefore encompass both 
pharmacogenomics and pharmacoproteomics, a more 
recently-emerged field which uses proteomic technolo-
gies for drug discovery and development [39]. Notably, 
analysis of the translation step between genome and pro-
teome is referred to as transcriptomics. The transcrip-
tome may be measured by such technologies as mRNA 
microarrays and RNA-seq [40]. As correlation between 
mRNA and protein may be low, transcriptomics may also 
be a critical component of integrated ‘omics’ approaches 
[41].
The term ‘pharmacoproteomics’ was not introduced in 
the literature until the early 2000s [39, 42, 43], near the 
beginning of a rapid growth period in the general field 
of proteomics and its technologies. While the number of 
publications termed with ‘pharmacogenomics’ or ‘phar-
macogenetics’ approaches well into the 10,000–20,000 
range, a PubMed search in June 2016 revealed only 166 
results for pharmacoproteomics, with the first having 
been published as a conference summary in 2002 [44]. 
Even today, there exists no standard definition for this 
branch of proteomics. This review will primarily focus on 
pharmacoproteomics as the use of proteomic analyses in 
drug discovery and development.
Although many discovered therapeutic targets enter 
the preclinical testing phase, the number of drugs that 
are eventually approved for human use is relatively minis-
cule, especially for oncology treatments [45]. Drug failure 
is often due to poor pharmacokinetic properties such as 
low bioavailability, poor absorption, pre-mature metabo-
lism, or adverse side effects. Pharmacoproteomics gives 
us the potential to study drug mechanisms at the pro-
teome level while at the same time investigating toxicity 
and resistance, or perhaps discovering new drug targets, 
early in the drug development process. In this manner, 
drugs with flawed properties can be saved from further 
development, while newer, better-performing drugs can 
be discovered and moved forward.
Pharmacoproteomics approaches and applications
Experimental workflows in proteomics approaches 
to drug screening and development, like genomics 
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approaches, may be broadly classified as targeted or 
global. Targeted approaches may involve affinity-based or 
activity-based profiling techniques, which employ chem-
ically-engineered probes to capture proteins of interest. 
Detailed discussion of targeted methods can be found 
in several informative book chapters and review articles 
[46–48]. While global methods are more challenging 
from a bioinformatics standpoint, they are advantageous 
because they provide unbiased, large-scale analyses and 
may reveal unexpected relationships among seemingly 
unrelated pathways. A typical in vitro workflow involves 
treating cells with the drug of interest, lysing the cells, 
digesting proteins into peptides, and then analyzing the 
entire proteome by mass spectrometry techniques. Sta-
ble isotope labeling with amino acids in cell culture 
(SILAC) is often used for accurate quantification [49]. 
Protein abundance is compared across drug-treated and 
untreated (control) conditions in order to probe the phe-
notypic pathways induced by the drug. Initial studies 
were likely biased towards the most abundant proteins, as 
analytical depth suffered with earlier analytical technolo-
gies. Advances in mass spectrometry, such as sensitivity, 
sample preparation methods, and data analysis capabili-
ties, now allow for the identification of over 10,000 pro-
teins in a cell line [50, 51], though current resolutions 
may remain too limited to detect some low-abundance 
markers in blood or tissue [52]. Furthermore, protein and 
peptide enrichment techniques permit the assessment 
of post-translational modifications such as phospho-
rylation, as demonstrated by Klammer et  al. with their 
identification of a protein phosphorylation signature to 
predict response to the antineoplastic agent dasatinib in 
non-small cell lung cancer cell lines [53]. Notably, pro-
tein or antibody arrays are another major technique to 
study proteomics that may offer increased analytical sen-
sitivities [54]. However, because such arrays require pre-
conceiving of the proteins to be investigated, the ‘open 
architecture’ of mass spectrometry may be more advan-
tageous for global, discovery studies.
A leading study in the pharmacoproteomic field, 
described by Ong et  al. [55], utilized quantitative pro-
teomic analysis of SILAC-labeled cell lysates to identify 
specific protein interactions and targets of small mol-
ecules, including kinase inhibitors and immunophi-
lin binders. Several investigations have since followed 
similar methods to identify targets of anti-cancer agents 
[56–58]. Results have often demonstrated that phar-
maceutical compounds elicit pharmacological effects 
through multiple protein targets that may be unrelated 
by genetic sequence, highlighting the importance of the 
broad proteomic approach to piece together complete 
mechanisms [59]. Furthermore, identification of mul-
tiple protein targets may lead to novel combinatorial 
therapies, particularly in cancer. A recent study utilized 
pharmacoproteomic approaches to identify and verify 
combined therapy towards B cell receptor (BCR) path-
ways and heat shock protein 90 (Hsp90) in diffuse large 
B cell lymphoma [60]. Pharmacoproteomics methodolo-
gies have been applied to a variety of other disease states, 
such as diabetes and neurovascular disease [61]. In par-
ticular, quantitative proteomics may shed light on the 
interaction of small molecules with the complex blood 
brain barrier [62].
Toxicoproteomics
Adverse reactions are a significant cause of drug failure in 
the drug development pipeline. Toxicoproteomic studies 
incorporate similar global protein expression technolo-
gies as described above but typically focus on either acute 
or chronic toxicity of the small molecule(s) in question 
[63]. Toxicoproteomics seeks to determine how chemi-
cal exposure modifies proteins or protein expression as 
a form of preclinical risk assessment. Quick and efficient 
identification of a molecule’s toxic effect means it may 
be spared from further progression down the pipeline, 
saving money and allowing for focus shifts to alterna-
tive molecules. Furthermore, identified protein changes 
may translate into new biomarkers that may be used to 
monitor treated patients for signatures of chemical tox-
icity. In terms of anticancer agents, toxicoproteomic 
studies aid in the detection of toxicity for ideally cancer 
cells only when compared to proteomic signatures of 
treated normal cells. A comprehensive compilation of 
published toxicoproteomic studies on drugs both in vitro 
(humans and animals) and in vivo (animals) is provided 
by Rabilloud and Lescuyer [64]. Analyses are sometimes 
targeted toward specific organ systems, often the liver 
or kidney [65], though it is important to consider that 
even the most targeted of drugs may have significant 
impacts system-wide. Notably, toxicoproteomic studies 
extend beyond the application of drug development and 
may be used to assess the toxic effects of other chemi-
cal agents such as environmental toxins and engineered 
nanomaterials.
Pharmacometabolomics
Metabolomics involves the broad characterization of 
small molecule metabolites in the cell or body fluid, rep-
resenting the final culmination of gene expression, pro-
tein expression, and environmental influences in order to 
characterize a metabolic signature of a sample or patient. 
In similar fashion to the aforementioned fields of study, 
pharmacometabolomics entails the comparison of this 
metabolic signature before and after drug exposure [66]. 
Outcomes of these studies may allow for better under-
standing of the mechanisms underlying heterogeneities 
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in drug response. Approaches may be targeted toward 
a pathway of interest or non-targeted and may utilize a 
variety of technical platforms. A recent study utilized 
GC–MS and NMR to identify distinct sets of metabo-
lites indicative of survival and of disease progression 
in serum from lung cancer patients undergoing stand-
ard chemotherapy or radiation regimens [67]. Another 
recent study used a targeted LC–MS/MS approach to 
investigate signatures of such compounds as amino 
acids, acylcarnitines, and lipids in serum upon neoadju-
vant trastuzumab-paclitaxel treatment in HER2-positive 
breast cancer patients. This group found that patients 
with favorable response to therapy exhibited signifi-
cantly higher amounts of spermidine and lower amounts 
of tryptophan when compared to poor responders [68]. 




It is clear that research findings from the ‘omics’ fields of 
study, i.e. pharmacogenomics, transcriptomics, pharma-
coproteomics, and associated areas of toxicoproteomics 
and pharmacometabolomics, should not be taken indi-
vidually but instead should inform and complement one 
another (Fig. 1). Until recently, simultaneously-combined 
genomics and proteomics studies (‘proteogenomics’) 
had rarely been undertaken. However, advancements 
in systems pharmacology technologies and data man-
agement have allowed for what should be considered 
just the beginning of such complementing studies. One 
large initiative with this approach in mind is the National 
Cancer Institute’s Clinical Proteomic Tumor Analy-
sis Consortium (CPTAC) [69]. The goal of the program 
is to identify potential cancer biomarker candidates by 
integrating genomic and proteomic analyses. In the “tar-
geting genome to proteome” approach, cancer-related 
genome alterations first identified by genomic studies are 
then targeted at the protein level by proteomic measure-
ments. In the “mapping proteome to genome” approach, 
broad-scale genomic and proteomic measurements are 
conducted simultaneously and then integrated. To date, 
this initiative has allowed for the unprecedented identifi-
cation of protein pathways associated with genomically-
annotated breast cancer samples [70] and our study on 
ovarian cancer samples [71]. These studies have identified 
novel therapeutic targets by linking genotype to pheno-
type, and ideally, further studies may compare the same 
genome and/or proteome data before and after treat-
ment with new therapies geared toward these targets. 
CPTAC centers, including ours, are actively developing 
assays to detect and correlate candidate biomarkers. The 
Fig. 1 Integration of ‘omics’ technologies for precision medicine. The realization of precision medicine via the discovery and development of 
biomarkers for disease detection, therapy, and prediction of drug response will involve the integration of technologies which analyze control and 
disease-relevant samples at the genomic, transcriptomic, and proteomic levels. This schematic details some examples of such technologies. NGS 
next-generation sequencing
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resulting databases, as well as assay details, are posted 
to a free online repository in order to foster collabora-
tion and standardization. Furthermore, in July 2016, NCI 
announced the launch of the Applied Proteogenom-
ics OrganizationaL Learning and Outcomes (APOLLO) 
Network, a tri-agency coalition involving CPTAC, the 
Department of Veterans Affairs, and the Department 
of Defense. Through APOLLO, cancer patients will be 
screened for both genomic and proteomic abnormalities 
in order to match the patients to personalized, targeted 
therapies. Initially, the program will focus on a cohort of 
8000 patients to investigate the genomics- and proteom-
ics-based individualization of lung cancer treatment.
Another joint initiative stems from two additional 
NIH-funded multi-institution networks: the Pharmacog-
enomics Research Network [72] and the Pharmacome-
tabolomics Research Network [73]. Concurrent genomic 
and metabolomics studies are conducted to, for instance, 
investigate whether genetic mutations identified as cor-
related with aberrant drug response are also associated 
with metabolites indicated for the same drug response. 
This approach has been coined by the networks as “phar-
macometabolomics-informed-pharmacogenomics” and 
thus far has been applied to investigate heterogeneities in 
responses from pharmaceutical agents including aspirin 
and selective serotonin reuptake inhibitors [74]. Kaddu-
rah-Daouk and Weinshilboum, along with the Pharmaco-
metabolomics Research Network, provide an informative 
compilation of affiliated pharmacometabolomic studies 
in a recent review [75].
Challenges in clinical translation
While exciting advancements are paving the way for com-
bined ‘omics’ investigations, several barriers still remain 
to translate resultant biomarkers into clinical practice. 
Practically, challenges remain in the proteomic assess-
ment of complex tissue and body fluids, and a majority 
of studies conducted to date are in vitro. Thus, identified 
candidates may need further verification via orthogonal, 
targeted approaches in more clinically-relevant matri-
ces. Data management continues to prove challenging 
with the tremendous amount of data that is generated by 
high-throughput and broad-screening technologies. Inte-
gration of data from various experiments amongst the 
collaborative networks in a logistical and standardized 
way will be imperative in order for investigators to feed 
off of one another to progress discoveries.
Furthermore, once data is mined and potential bio-
markers are identified, those candidate markers must 
be progressed forward to independent validation stud-
ies before they can be translated into the realm of clini-
cal diagnostics. Further investigations should assess: (a) 
the utility of the markers in clinical outcomes studies, (b) 
how measurements of the markers should be interpreted 
and acted upon, and (c) the cost-effectiveness of imple-
menting the monitoring of the markers. The lack of such 
clinical validation studies remains a significant obstacle 
for the implementation of pharmacogenomic and phar-
macoproteomic markers alike and is a large reason that 
testing of many well-established pharmacogenetic poly-
morphisms is not widely utilized and reimbursed [36].
For similar reasons, FDA approval of assays detecting 
laboratory-discovered proteomic and genomic biomark-
ers is slow. In the case of pharmacogenomics, there is a 
combined desire for the FDA’s inclusion of genetic test 
indications on the drug label in addition to FDA approval 
of the corresponding genetic test itself. Progress has been 
made steadily, and currently more than 100 drug labels 
contain pharmacogenetic information specifying genetic 
biomarkers that may be indicated for safe use of the 
drug [76, 77]. As of this publication, twelve commercial 
nucleic acid-based assays are FDA cleared or approved 
in the ‘drug metabolizing enzyme’ category [78], many 
for CYP2C9 for the identification of warfarin sensitivity. 
However, some hospital laboratories conducting phar-
macogenetic testing are using laboratory-developed tests 
(LDTs). It remains to be seen how upcoming changes 
in FDA oversight of LDTs will impact pharmacogenetic 
testing [79, 80]. On the pharmacoproteomic side, chal-
lenges in approving proteomic biomarkers for clinical 
practice often include limitations in both analytical per-
formance (i.e. precision, accuracy, sensitivity, specificity) 
and clinical performance, perhaps due to complexities in 
both sample preparation and spectra analysis methods 
[81, 82]. These limitations have raised issues of reproduc-
ibility with proteomics and have made harmonization of 
assays difficult across multiple laboratory sites. However, 
a recent significant multi-center study has demonstrated 
that standardization of both analytical and pre-analytical 
protocols can make possible the reproducibility of mass 
spectrometric measurement of proteins [83]. Further, 
genomic and transcriptomic technologies are currently 
universally considered highly reproducible [84].
Future outlook and conclusions
Many diseases are in need of biomarker discovery of tar-
gets for treatment and monitoring and could therefore 
benefit tremendously from integrated ‘omics’ approaches. 
Cancer may be one of the most appropriate immedi-
ate focuses due to its inherent complexity and the large 
number of cancer genomes which have already been 
sequenced through collaborative efforts (i.e. the Cancer 
Genome Atlas [85] and the International Cancer Genome 
Consortium [86]). Other critical applications include the 
growing health problems in our nation of diabetes and 
metabolic syndrome. Longitudinal gathering of genomic, 
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transcriptomic, and proteomic data among patients 
at-risk for these disorders may provide insight into the 
mechanisms behind disease progression and reveal tar-
gets for disease detection, treatment, and monitoring. 
Further advances in integrated data management will be 
critical for these studies to be successful.
As genomic and proteomic methodologies prove their 
analytical performance and clinical utility, become more 
accessible and routine, and perhaps more portable [87], 
one may imagine a treatment model by which such 
measurements may be taken at the bedside. Pharma-
cogenetic screening for risks of adverse drug reactions 
would guide drug prescription and dosing on the front 
end of treatment, while pharmacoproteomic measure-
ments taken before, during, and after interventional 
therapy would aid in monitoring triggered phenotypic 
changes. Standardization of both detection method-
ologies and electronic healthcare databases will be criti-
cal such that patients can be followed longitudinally 
throughout this process.
In conclusion, personalized ‘omics’ approaches, both at 
the genome and proteome levels, are actively improving 
our understanding of disease and drug mechanisms and 
are allowing for the discovery, detection, and monitor-
ing of novel biomarkers for a variety of complex diseases 
and their treatments. By integrating pharmacoproteomic 
profiles with pharmacogenomics databases, precision 
medicine may be eventually fulfilled via diagnosing test-
ing to identify the right therapeutic regimen for the right 
patient.
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